Major depressive disorders have recently been associated with impairments in signaling
pathways that regulate neuroplasticity and cell survival. Agents designed to directly target …

The prevalence of depression has dramatically increased, and it has been estimated that
over 300 million people suffer from depression all over the world. Depression is highly …

The limited effects of currently available antidepressants are becoming an urgent issue in
depression research. It takes a long time to determine treatment effects, and the overall …

Parkinson's disease (PD) is characterized mainly by motor dysfunctions due to the
progressive loss of dopaminergic neurons. However, PD patients experience a multitude of …

Depression is a common and devastating neuropsychiatric symptom in the elderly and in
patients with dementia. In particular, nearly 80% of patients with Alzheimer's Disease …

Alzheimer disease (AD) is a devastating neurodegenerative disorder that affects millions of
individuals worldwide, with no effective cure. The main symptoms include learning and …

Major depressive disorder (MDD) is a common and devastating psychiatric disorder
characterized by persistent low mood, cognitive disorder, and impaired social function …

The need for newer compounds to treat depression is an ever-growing concern due to the
enormous societal and financial ramifications of this disorder. Here, we review some of the …

Since 1906, when Dr. Alois Alzheimer first described in a patient “a peculiar severe disease
process of the cerebral cortex”, people suffering from this pathology have been waiting for a …

Alzheimer's disease (AD) belongs to one of the most multifactorial, complex and
heterogeneous morbidity‐leading disorders. Despite the extensive research in the field, AD …